Get started
Author

Andrew J. Martin

Observed institution: St George's Hospital
ORCID: 0009-0006-3232-7819
Observed ORCID: 0009-0006-3232-7819
OpenAlex ID: A5134739875
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al. · Clinical Cancer Research · 3
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplemental Tables 1-2 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026 · Crescens Tiu, Wing Yau, et al.
Works count: 10
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type